Taken together, our findings do not support a direct link between the adipokines leptin, resistin, and adiponectin and the reduction in CVD risk observed following initiation of TCZ treatment in RA patients, and may suggest that other adipokines or cytokines may play a greater role in mediating this effect, as was recently suggested [24], or that other mechanisms play a cardioprotective role in RA patients treated with this biologic agent. This evidence concerns the gene LEP and rheumatoid arthritis.